Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study.

Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, Deering MM, Schwartz BL, Abuzzahab MJ, Gandrud LM, Moran A, Billington CJ, Schwarzenberg SJ

Obesity (Silver Spring, Md.)10 Nov 2011Cited by 113 (Europe PMC)

PMID22076596PMCIDPMC3684414DOI10.1038/oby.2011.337PepBankPUB-22076596

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In youth with extreme obesity, exenatide plus lifestyle modification reduced BMI versus lifestyle modification alone.
In plain wordsIn youth with extreme obesity, exenatide plus lifestyle changes reduced BMI more than lifestyle changes alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBMI
Study
n = 12
Comparator
Lifestyle modification alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
BMI treatment difference
−1.7 kg/m(2)
exenatide versus control
Source sentences
Summary
Compared to control, exenatide significantly reduced BMI (-1.7 kg/m(2), 95% confidence interval (CI) (-3.0, -0.4), P = 0.01), body weight (-3.9 kg, 95% CI (-7.11, -0.69), P = 0.02), and fasting insulin (-7.5 mU/l, 95% CI (-13.71, -1.37), P = 0.02).
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of this pilot study was to evaluate the effects of exenatide on BMI (primary endpoint) and cardiometabolic risk factors in nondiabetic youth with extreme obesity.
Summary · context
Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI ≥1.2 times the 95th percentile or BMI ≥35 kg/m(2)) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a…
Summary · context
The mean change over each 3-month phase was compared between treatments.
Report a problemFND-2207659601
02HumanRandomized controlled trialEfficacy outcome
In youth with extreme obesity, exenatide plus lifestyle modification reduced body weight versus lifestyle modification alone.
In plain wordsIn youth with extreme obesity, exenatide plus lifestyle changes reduced weight more than lifestyle changes alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 12
Comparator
Lifestyle modification alone
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
Weight treatment difference
−3.9 kg
exenatide versus control
Source sentences
Summary
Compared to control, exenatide significantly reduced BMI (-1.7 kg/m(2), 95% confidence interval (CI) (-3.0, -0.4), P = 0.01), body weight (-3.9 kg, 95% CI (-7.11, -0.69), P = 0.02), and fasting insulin (-7.5 mU/l, 95% CI (-13.71, -1.37), P = 0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI ≥1.2 times the 95th percentile or BMI ≥35 kg/m(2)) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a…
Summary · context
The mean change over each 3-month phase was compared between treatments.
Report a problemFND-2207659602
03HumanRandomized controlled trialEfficacy outcome
In youth with extreme obesity, exenatide plus lifestyle modification reduced fasting insulin versus lifestyle modification alone.
In plain wordsIn youth with extreme obesity, exenatide plus lifestyle changes reduced fasting insulin more than lifestyle changes alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting insulin
Study
n = 12
Comparator
Lifestyle modification alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
Fasting insulin treatment difference
−7.5 mU/l
exenatide versus control
Source sentences
Summary
Compared to control, exenatide significantly reduced BMI (-1.7 kg/m(2), 95% confidence interval (CI) (-3.0, -0.4), P = 0.01), body weight (-3.9 kg, 95% CI (-7.11, -0.69), P = 0.02), and fasting insulin (-7.5 mU/l, 95% CI (-13.71, -1.37), P = 0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI ≥1.2 times the 95th percentile or BMI ≥35 kg/m(2)) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a…
Summary · context
The mean change over each 3-month phase was compared between treatments.
Report a problemFND-2207659603
04HumanRandomized controlled trialEfficacy outcome
In youth with extreme obesity, exenatide improved OGTT-derived insulin sensitivity versus lifestyle modification alone.
In plain wordsIn youth with extreme obesity, exenatide improved insulin sensitivity compared with lifestyle changes alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseOGTT-derived insulin sensitivity
Study
n = 12
Comparator
Lifestyle modification alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Significant improvements were observed for OGTT-derived insulin sensitivity (P = 0.02) and β-cell function (P = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI ≥1.2 times the 95th percentile or BMI ≥35 kg/m(2)) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a…
Summary · context
The mean change over each 3-month phase was compared between treatments.
Report a problemFND-2207659604
05HumanRandomized controlled trialEfficacy outcome
In youth with extreme obesity, exenatide improved beta-cell function versus lifestyle modification alone.
In plain wordsIn youth with extreme obesity, exenatide improved beta-cell function compared with lifestyle changes alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBeta-cell function
Study
n = 12
Comparator
Lifestyle modification alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Summary
Significant improvements were observed for OGTT-derived insulin sensitivity (P = 0.02) and β-cell function (P = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI ≥1.2 times the 95th percentile or BMI ≥35 kg/m(2)) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a…
Summary · context
The mean change over each 3-month phase was compared between treatments.
Report a problemFND-2207659605
06HumanRandomized controlled trialOther
In youth with extreme obesity, adherence to the exenatide injection regimen was at least 94%.
In plain wordsIn youth with extreme obesity, adherence to exenatide injections was at least 94%.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableInjection regimen adherence
Study
n = 12
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
Injection adherence
≥ 94%
exenatide regimen
Source sentences
Summary
Compliance with the injection regimen was excellent (≥94%) and exenatide was generally well-tolerated (the most common adverse event was mild nausea in 36%).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI ≥1.2 times the 95th percentile or BMI ≥35 kg/m(2)) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a…
Summary · context
The mean change over each 3-month phase was compared between treatments.
Report a problemFND-2207659606
07HumanRandomized controlled trialSafety outcome
In youth with extreme obesity, mild nausea was the most common exenatide adverse event, occurring in 36%.
In plain wordsIn youth with extreme obesity, mild nausea occurred in 36% during exenatide treatment and was the most common adverse event.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableMild nausea
Study
n = 12
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
Mild nausea
36%
exenatide
Source sentences
Summary
Compliance with the injection regimen was excellent (≥94%) and exenatide was generally well-tolerated (the most common adverse event was mild nausea in 36%).
2 context sentences(design, population, supporting numbers)
Summary · context
Twelve children and adolescents (age 9-16 years old) with extreme obesity (BMI ≥1.2 times the 95th percentile or BMI ≥35 kg/m(2)) were enrolled in a 6-month, randomized, open-label, crossover, clinical trial consisting of two, 3-month phases: (i) a control phase of lifestyle modification and (ii) a…
Summary · context
The mean change over each 3-month phase was compared between treatments.
Report a problemFND-2207659607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00886626

GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

University of Minnesotan = 12May 2009 to Feb 2011

Obesity, Morbid

Trial page ClinicalTrials.govUpdated 29 Oct 2012

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.